English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
UrduCombining Orionis’ unique high-throughput drug discovery technologies with the Therapeutics Discovery division’s expertise in small-molecule therapies and translational biology, Project Helios aims to create an unparalleled collection of drug-target interaction data to enable rational drug discovery, optimization and repurposing. The project will focus initially on developing therapies for unmet needs in oncology, with the possibility of expanding to additional therapeutic areas in the future.
“We are excited to be collaborating with MD Anderson’s Therapeutics Discovery team in launching Project Helios, a fundamental step toward new approaches in drug discovery that will enlighten our understanding of the dark proteome. This effort will build on a wealth of public data, chemical and clinical knowledge that has been assembled over many years across the pharmaceutical industry and biomedical institutions,” said Niko Kley, chief executive officer at Orionis.
Molecular interactions between small-molecule drugs and proteins define both their therapeutic efficacy as well as undesired adverse effects. A comprehensive unraveling of these interactions is fundamentally important both for illuminating new drug development opportunities and devising safer medicines with fewer related toxicities.
“We are pleased to be collaborating with Orionis on this exciting initiative to understand drug-target interactions at a new level of detail. The intersection of the data from Project Helios with the unparalleled translational research and drug discovery capabilities at MD Anderson should yield important insights for therapeutics development, hopefully resulting in impactful new medicines for patients with cancer,” said Philip Jones, Ph.D., vice president of Therapeutics Discovery at MD Anderson.
Project Helios will conduct systematic and unbiased mapping of drug interactions across the human proteome with a large portfolio of bioactive, chemically diverse small molecules, including experimental and approved drugs. The findings may provide opportunities to repurpose approved therapies, optimize therapeutic approaches for known targets and develop therapies for novel targets.
“We expect Project Helios to generate a unique data set for the application of new machine-learning models for multivariate, genomic-scale drug design and to further illuminate what we refer to as the ‘Drug Pocketome’ [small-molecule binding sites on drug targets],” said Riccardo Sabatini, chief data scientist at Orionis.
– 30 –
